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Natural Killer cells (NK cells) are lymphocytes able to
recognize and kill tumors for which the expression of
Major Histocompatibility Complex (MHC) class I mole-
cules is altered. This “missing self” recognition is
mediated in humans by the lack of engagement of MHC
class I i.e. Human Leucocyte Antigens (HLA) molecules
with NK cell inhibitory receptors that include Killer
Immunoglobulin-like Receptors (KIR). Some tumors
escape NK cell immune surveillance by increasing the
expression of HLA molecules on their surface. Conse-
quently, blocking interactions between KIR and HLA
molecules constitutes an interesting therapeutic strategy.
The anti-KIR2DL1/2/3-specific monoclonal antibody,
lirilumab/BMS-986015/IPH2102, is a human IgG4 that
is being developed for treating both hematologic malig-
nancies and solid tumors. In rodents, the MHC class I
inhibitory system regulating NK cell activation is based
on lectin-like family Ly49 but the KIR molecules are not
expressed. The objective of this study was to develop a
preclinical model to assess the efficacy of the drug can-
didate used in clinical trials, lirilumab. Mice expressing
the human NK inhibitory KIR2DL3, on the surface of
NK cells were generated on a RAG-1deficient back-
ground (KIRtgRAG mice). The human B cell lymphoma
cell line, 721.221, transduced with HLA-Cw3 molecule,
a ligand of KIR2DL3, was intra-venously engrafted in
these mice. The expression of HLA-C by tumor cells
was sufficient to allow them to escape control of NK
cells, leading to mice death in around 30 days. Lirilumab
treatment increased mice survival in a dose dependent
manner when injected at the same time as the tumor
challenge. This protective effect was NK cell-mediated
and directly correlated with the duration of KIR satura-
tion. Interestingly, lirilumab treatment also improved
survival in therapeutic conditions i.e. when the antibody
was injected 5 days after the tumor, also in a NK cell-
dependent manner. In conclusion, this study showed
efficacy of lirilumab as single agent in a HLA-Cw3-
expressing tumor model and this xenogenic pre-clinical
model will be an excellent tool to investigate the thera-
peutic benefits of combination treatments.
Authors’ details
1Innate Pharma, Marseille, France. 2Centre d’Immunologie de Marseille-
Luminy, Université d’Aix-Marseille, Marseille, France. 3Bristol-Myers Squibb,
Princeton, NJ, USA.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P40
Cite this article as: Sola et al.: Anti-tumoral efficacy of therapeutic
human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a
preclinical xenograft tumor model. Journal for ImmunoTherapy of Cancer
2013 1(Suppl 1):P40.
1Innate Pharma, Marseille, France
Full list of author information is available at the end of the article
Sola et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P40
http://www.immunotherapyofcancer.org/content/1/S1/P40
© 2013 Sola et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
